Publications by authors named "Luis A Rodriguez de Antonio"
Real-World Experience with Diroximel Fumarate in Patients with Multiple Sclerosis: A Prospective Multicenter Study.
Clin Drug Investig
November 2024
Background: Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.
Objectives: This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world setting, utilizing data from a Spanish national registry of patients commencing DRF therapy post-market introduction.
Objectives: To compare the clinical and radiological effectiveness of ocrelizumab in primary progressive multiple sclerosis (PPMS) and relapsing-remitting multiple sclerosis (RRMS) in a clinical practice setting and describe its tolerability and adverse events.
Methods: A retrospective observational cohort study was conducted comparing clinical and magnetic resonance imaging (MRI) data of all patients with (pw)PPMS and RRMS who had received treatment with ocrelizumab at least one cycle and have been followed up for one year at minimum.
Results: 42 patients (27 women) treated with ocrelizumab: 29 had RRMS and 13 PPMS.
Article Synopsis
- The study aimed to understand how inflammation affects the response to ocrelizumab treatment in patients with primary-progressive multiple sclerosis (PPMS).
- Researchers followed 69 patients, looking at those with and without gadolinium-enhancing lesions on MRI, finding that over 60% achieved "no evidence of disease activity" (NEDA) after one year.
- The results suggested that in patients with Gd+ lesions, a low rate of inflammatory B cells and decreased serum neurofilament levels were significant, while in Gd- patients, NEDA was associated with changes in other immune cells and increased serum IgA levels.
Objective: To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments.
Methods: Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome.
Background: Even though SARS-CoV-2 is a predominantly respiratory virus, several reports have described various neurological disorders, from the beginning of the pandemic. The first para-infectious myelitis case was described in Wuhan in February 2020. Nevertheless, data from registries and reviews are scarce.
View Article and Find Full Text PDFEffect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.
Neurol Neuroimmunol Neuroinflamm
March 2021
Objective: To analyze the changes induced by ocrelizumab in blood immune cells of patients with primary progressive MS (PPMS).
Methods: In this multicenter prospective study including 53 patients with PPMS who initiated ocrelizumab treatment, we determined effector, memory, and regulatory cells by flow cytometry at baseline and after 6 months of therapy. Wilcoxon matched paired tests were used to assess differences between baseline and 6 months' results.
Introduction: Cardiological complications are the most frequent cause of mortality in the epileptic status. Takotsubo cardio-myopathy is a recently reported condition that can appear in a number of medical emergencies, including epileptic status.
Case Report: We present a case of Takotsubo cardiomyopathy within the context of an epileptic status and we also review similar cases reported in the literature.